UK markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
11,064.00+102.00 (+0.93%)
At close: 06:15PM BST

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees89,900

Key executives

NameTitlePayExercisedYear born
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Executive Director4.57MN/A1959
Dr. Aradhana Sarin M.D.CFO & Executive Director2.52MN/A1974
Ms. Pam P. ChengEVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. BoardN/AN/A1970
Mr. Andrew P. BarnettHead of Investor RelationsN/AN/AN/A
Mr. Jeffrey PottCHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory BoardN/AN/AN/A
Gonzalo VinaHead of Global Media RelationsN/AN/AN/A
Dr. Menelas Nicolas Pangalos Ph.D.Executive Vice-PresidentN/AN/A1967
Dr. Ruud Dobber Ph.D.Executive Vice-President of BioPharmaceuticals Business UnitN/AN/AN/A
Dr. Susan Mary Galbraith M.D., Ph.D.Executive Vice President of Oncology Research & DevelopmentN/AN/A1966
Mr. Leon WangExecutive VP of International & China PresidentN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate governance

AstraZeneca PLC’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 5; Board: 3; Shareholder rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.